GH Research (NASDAQ:GHRS) Shares Down 7.4% - Should You Sell?

GH Research PLC (NASDAQ:GHRS - Get Free Report) traded down 7.4% during mid-day trading on Friday . The stock traded as low as $11.34 and last traded at $11.34. 24,727 shares were traded during mid-day trading, a decline of 95% from the average session volume of 511,182 shares. The stock had previously closed at $12.25.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the stock. Cantor Fitzgerald initiated coverage on shares of GH Research in a research report on Thursday, February 13th. They set an "overweight" rating and a $14.00 price target for the company. HC Wainwright reissued a "buy" rating and issued a $40.00 target price on shares of GH Research in a report on Monday, January 27th. Royal Bank of Canada started coverage on GH Research in a research note on Friday, March 7th. They issued an "outperform" rating and a $31.00 price target for the company. Stifel Nicolaus increased their price objective on GH Research from $18.00 to $32.00 and gave the company a "buy" rating in a research report on Thursday, February 27th. Finally, Guggenheim assumed coverage on GH Research in a research report on Thursday, March 13th. They issued a "buy" rating and a $32.00 target price for the company. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has a consensus rating of "Buy" and an average price target of $30.86.

GH Research Stock Down 0.3 %

The business's fifty day moving average is $11.80 and its 200-day moving average is $9.37. The company has a market cap of $573.87 million, a PE ratio of -13.96 and a beta of 0.94.

Remove Ads

GH Research (NASDAQ:GHRS - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.17) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.06. Analysts forecast that GH Research PLC will post -0.8 EPS for the current fiscal year.

Institutional Investors Weigh In On GH Research

Institutional investors have recently bought and sold shares of the business. Geode Capital Management LLC boosted its stake in shares of GH Research by 4.5% in the fourth quarter. Geode Capital Management LLC now owns 72,513 shares of the company's stock worth $508,000 after acquiring an additional 3,092 shares during the period. AdvisorShares Investments LLC lifted its holdings in GH Research by 15.4% in the 4th quarter. AdvisorShares Investments LLC now owns 36,011 shares of the company's stock worth $252,000 after purchasing an additional 4,806 shares in the last quarter. BNP Paribas Financial Markets bought a new position in GH Research in the 4th quarter worth approximately $44,000. Northern Trust Corp grew its holdings in GH Research by 26.8% during the 4th quarter. Northern Trust Corp now owns 40,834 shares of the company's stock valued at $286,000 after buying an additional 8,641 shares in the last quarter. Finally, Two Sigma Investments LP purchased a new stake in GH Research during the 4th quarter valued at approximately $117,000. Hedge funds and other institutional investors own 56.90% of the company's stock.

About GH Research

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).